Clinical Trial Search

Primary: Number of Sexual Partners, 3 Months Post Intervention — 2.19; 2.04; 2.14; 2.13 number of partners

Primary: GC/CT Detection Rates — 15.2; 12.1; 11 No. of patients with positive GC/CT

Primary: Efficacy of Internet-based Program for Increasing Condom Use With Non-main Sex Partners — .68; .56 percentage of sex acts protected by cond

Primary: Number of Participants That Schedule a Pre-test Session — 74 Participants

Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…

Primary: Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults — 15; 2; 6; 108 Participants…

Primary: Number of Quarterly Visits In Which an STI Was Detected — 61; 82; 36; 39 No. quarterly visits with STI event

Primary: Measurement of Acceptance Rate of PrEP — 921; 557 Participants

Primary: Doxycycline Concentration in Rectal Tissue — 2.330 µg/g

Primary: STI Incidence — 250; 226 participants

Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale

Primary: Number of Respondents Who Responded YES to Any Question Defining High Risk Penicillin Allergy Using Questionnaire Developed by the Study — 36; 36 Participants

Primary: Dual Protection Behaviors, Reported in Surveys and Reviewed in the Medical Record. — 7; 6; 8; 8 Participants

Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001

Primary: Mean Number of Doses of HBV Vaccine Received — .78; .85; .94; .98 Doses of HBV Vaccine — p==.885

Primary: Change in Prevention Self-efficacy — 1.87; 0.20 score on a scale — p=0.04

Primary: Feasibility as Assessed by the Number of Participants Who Are Enrolled With a Partner — 17; 17 Participants

Primary: Microbiological Efficacy of Gentamicin and Azithromycin for the Treatment of Uncomplicated Gonococcal Infection — 100 percentage of participants — p=<0.05

Primary: Incidence of N. Gonorrhoeae, C. Trachomatis, or Early Syphilis Infection by Laboratory-based Diagnosis — 25.1; 29.0 Events per 100 person-years

Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053

Primary: Number of Participants With Risky Sexual Behavior Measured for 1 Year — 143; 155; 162 Participants

Primary: Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) — 27; 28 participants

Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants

Primary: doxyPEP DOT Adherence — 1417 Doses

Primary: Initiation of Sexual Intercourse — 308; 509 participants

Primary: Consistent (100%) Condom Use — 9; 6; 7; 7 Participants — p=<.05

Primary: Number of Participants With Continuous Use of Highly Effective Contraceptives Over 9 Months. — 39; 29 Participants — p=>.05

Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…

Primary: Sex Risk Behaviors: Number of Sex Partners (>=2 Sex Partners) — 17; 29; 50; 53 participants — p=<0.01

Primary: The Number of Participants Who Are Able to Self-administer the DPP® HIV-Syphilis Test With mLab App Plus — 12 Participants